Health Condition


About This Condition

Cardiomyopathy refers to abnormalities in the structure or function of the heart muscle. There are three major types of cardiomyopathy: dilated congestive, hypertrophic, and restrictive.

The most prevalent form is dilated congestive cardiomyopathy (DCM). In people with DCM, the heart muscle is damaged, most commonly by coronary artery disease (atherosclerosis).1 People with diabetes have been reported to be at increased risk of DCM.2 DCM can also be triggered by alcohol abuse, infections, exposure to certain drugs and toxins, nutritional deficiencies, connective tissue diseases, hereditary disorders, and pregnancy.

In DCM, the heart gradually loses its efficiency as a pump. Cardiomyopathy is a serious health condition and requires expert medical care rather than self-treatment. However, because of the associations between cardiomyopathy and diseases such as atherosclerosis, diabetes, hypertension, and congestive heart failure, lifestyle recommendations for the prevention of these conditions may also help prevent DCM.

Hypertrophic cardiomyopathy is usually a hereditary disorder, although the incidence of this form of cardiomyopathy may also be higher in people with hypertension.3 Restrictive cardiomyopathy is usually due to a connective tissue disease, cancer, or an autoimmune condition. Both hypertrophic and restrictive cardiomyopathies are relatively uncommon.


People with cardiomyopathy may have difficulty breathing during light exertion, and they may become fatigued easily. Other chronic symptoms are swelling around the ankles and an enlarged abdomen.

Other Therapies

Severe cases might require heart transplantation surgery.


1. Beers MH and Berkow R, eds. The Merck Manual, 17th ed. Whitehouse Station, NJ: Merck and Co., Inc., 1999, 1692.

2. Coughlin SS, Pearle DL, Baughman KL, et al. Diabetes mellitus and risk of idiopathic dilated cardiomyopathy. The Washington, DC Dilated Cardiomyopathy Study. Ann Epidemiol 1994;4(1):67-74.

3. Post WS, Larson MG, Levy D. Hemodynamic predictors of incident hypertension. The Framingham Heart Study. Hypertension 1994;24(5):585-90.

4. Dwivedi S, Jauhari R. Beneficial effects of Terminalia arjuna in coronary artery disease. Indian Heart J 1997;49:507-10.

5. Bharani A, Ganguly A, Bhargava KD. Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure. Int J Cardiol 1995;49:191-9.

6. Manzoli U, Rossi E, Littarru GP, et al. Coenzyme Q10 in dilated cardiomyopathy. Int J Tissue React 1990;12(3):173-8.

7. Pogessi L, Galanti G, Comeglio M, et al. Effect of coenzyme Q10 on left ventricular function in patients with dilative cardiomyopathy. Curr Ther Res 1991;49:878-86.

8. Langsjoen PH, Vadhanavikit S, Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. Proc Natl Acad Sci U S A 1985;82:4240-4.

9. Ma A, Zhang W, Liu Z. Effect of protection and repair of injury of mitochondrial membrane-phospholipid on prognosis in patients with dilated cardiomyopathy. Blood Press Suppl 1996;3:53-5.

10. Belardinelli R, Georgiou D, Cianci G, et al. Effects of exercise training on left ventricular filling at rest and during exercise in patients with ischemic cardiomyopathy and severe left ventricular systolic dysfunction. Am Heart J 1996;132(1 Pt 1):61-70.

11. Bresolin N, Doriguzzi C, Ponzetto C, et al. Ubidecarenone in the treatment of mitochondrial myopathies: a multi-center double-blind trial. J Neurol Sci 1990;100:70-8.

12. Permanetter B, Rossey W, Weingartner F, et al. Lack of effectiveness of coenzyme Q10 (Ubiquinone) in long-term treatment of dilated cardiomyopathy. Z Kardiol 1989;78:360-5 [in German].

13. Lindner E, Dohadwalla AN, Bhattacharya BK. Positive inotropic and blood pressure lowering activity of a diterpene derivative isolated from Coleus forskohli: Forskolin. Arzneimittelforschung. 1978;28:284-9.

14. Baumann G, Felix S, Sattelberger U, Klein G. Cardiovascular effects of forskolin (HL 362) in patients with idiopathic congestive cardiomyopathy—a comparative study with dobutamine and sodium nitroprusside. J Cardiovasc Pharmacol 1990;16:93-100.

15. Kramer W, Thormann J, Kindler M, Schlepper M. Effects of forskolin on left ventricular function in dilated cardiomyopathy. Arzneimittelforschung 1987;37:364-7.

16. Takeo S, Tanonaka K, Hirai K, et al. Beneficial effect of tan-shen, an extract from the root of Salvia, on post-hypoxic recovery of cardiac contractile force. Biochem Pharmacol 1990 40:1137-43.

17. Bai YR, Wang SZ. Hemodynamic study on nitroglycerin compared with Salvia miltiorrhiza. Chung Kuo Chung Hsi I Chieh Ho Tsa Chih 1994;14:24-5 [in Chinese].

18. Xing ZQ, Zeng XC, Yi CT. Effect of Salvia miltiorrhiza on serum lipid peroxide, superoxide dismutase of the patients with coronary heart disease. Chung Kuo Chung Hsi I Chieh Ho Tsa Chih 1996;16:287-8 [in Chinese].

19. Paulson DJ. Carnitine deficiency-induced cardiomyopathy. Mol Cell Biochem 1998;180(1-2):33-41.

20. Winter S, Jue K, Prochazka J, et al. The role of L-carnitine in pediatric cardiomyopathy. J Child Neurol 1995;10 Suppl 2:S45-51.

21. Kothari SS, Sharma M. L-carnitine in children with idiopathic dilated cardiomyopathy. Indian Heart J 1998;50:59-61.

22. Kittleson MD, Keene B, Pion PD, Loyer CG. Results of the multicenter spaniel trial (MUST): taurine- and carnitine-responsive dilated cardiomyopathy in American cocker spaniels with decreased plasma taurine concentration. J Vet Intern Med 1997;11:204-11.

23. Pion PD, Kittleson MD, Thomas WP, et al. Response of cats with dilated cardiomyopathy to taurine supplementation. J Am Vet Med Assoc 1992;201:275-84.

24. McKenna CJ, Codd MB, McCann HA, Sugrue DD. Alcohol consumption and idiopathic dilated cardiomyopathy: a case control study. Am Heart J 1998;135(5 Pt 1):833-7.

25. Hoyumpa AM. Mechanisms of vitamin deficiencies in alcoholism. Alcohol Clin Exp Res 1986;10(6):573-81.

26. Lieber CS. Alcohol-nutrition interaction: 1984 update. Alcohol 1984;1(2):151-7.

27. Klatsky AL. The cardiovascular effects of alcohol. Alcohol 1987;Suppl 1:117-24.

28. Friedman HS. Cardiovascular effects of alcohol with particular reference to the heart. Alcohol 1984;1(4):333-9.

29. Urbano-Marquez A, Estruch R, Fernandez-Sola J, et al. The greater risk of alcoholic cardiomyopathy and myopathy in women compared with men. JAMA 1995;274(2):149-54.

30. Valgaeren G, Conraads V, Colpaert C, et al. Sudden death in hypertrophic cardiomyopathy: risk stratification and prevention. Acta Cardiol 1998;53(1):23-9.

31. Belardinelli R, Georgiou D, Cianci G, et al. Effects of exercise training on left ventricular filling at rest and during exercise in patients with ischemic cardiomyopathy and severe left ventricular systolic dysfunction. Am Heart J 1996;132(1 Pt 1):61-70.

32. Belardinelli R, Georgiou D, Cianci G, et al. Exercise training improves left ventricular diastolic filling in patients with dilated cardiomyopathy. Clinical and prognostic implications. Circulation 1995;91(11):2775-84.

33. Wielenga RP, Erdman RA, Huisveld IA, et al. Effect of exercise training on quality of life in patients with chronic heart failure. J Psychosom Res 1998;45(5):459-64.

34. Hambrecht R, Fiehn E, Weigl C, et al. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation 1998;98(24):2709-15.

35. Coughlin SS, Neaton JD, Sengupta A, Kuller LH. Predictors of mortality from idiopathic dilated cardiomyopathy in 356,222 men screened for the Multiple Risk Factor Intervention Trial. Am J Epidemiol 1994;139(2):166-72.

36. Hartz AJ, Ratner ER, Sinoway LI, Bartholomew MJ. Smoking and idiopathic congestive cardiomyopathy. Jpn Heart J 1996;37(3):401-7.

37. Juilliere Y, Danchin N, Briancon S, et al. Dilated cardiomyopathy: long-term follow-up and predictors of survival. Int J Cardiol 1988;21(3):269-77.

38. Metayer C, Coughlin SS, Mather FJ. Does cigarette smoking paradoxically increase survival in idiopathic dilated cardiomyopathy? The Washington, D.C., Dilated Cardiomyopathy Study. Cardiology 1996;87(6):502-8.

Copyright © 2020 TraceGains, Inc. All rights reserved.

Learn more about TraceGains, the company.

The information presented by TraceGains is for informational purposes only. It is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. Self-treatment is not recommended for life-threatening conditions that require medical treatment under a doctor's care. For many of the conditions discussed, treatment with prescription or over the counter medication is also available. Consult your doctor, practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications. Information expires December 2020.